Impacting Policy

ISARIC4C Tier 0/CO-CIN fed data dynamically through the Outbreak Data Analysis Platform (ODAP) to Public Health
Scotland, Public Health England, SPI-M, NERVTAG and SAGE. SPI-M have
been highly productive and published several analysis that informed
Policy.

The data were used to inform the NHS England Independent Advisory Group concerning the use of neutralising monoclonal antibodies and anti-viral drugs in high-risk clinical subgroups.

Other key UK policy documents citing ISARIC4C/ODAP data

1. COVID-19: the green book, chapter 14a.

   a. cites Docherty AB, et al. Features of 20133 UK patients in
   hospital with covid-19 using the ISARIC WHO Clinical
   Characterisation Protocol: prospective observational cohort
   study https://doi.org/10.1136/bmj.m1985

   b. Swann OV, et al. Clinical Characteristics of children and young
   people admitted to hospital with COVID-19 in United Kingdom:
   prospective multicentre observational cohort study
   https://doi.org/10.1136/bmj.m3249

2. Remdesivir – national prescribing guidance